Drug Profile
Research programme: non-alcoholic steatohepatitis therapeutics - Yuhan Corporation
Alternative Names: YH NCE5; YH NCE6; YH-NCE9Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Yuhan
- Class Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in South Korea
- 27 Nov 2017 Early research in Non-alcoholic steatohepatitis in South Korea for before November 2018 (Yuhan pipeline, November 2017)